Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1996 1
1997 4
1998 8
1999 1
2000 7
2001 5
2002 11
2003 11
2004 7
2005 15
2006 14
2007 18
2008 19
2009 13
2010 16
2011 15
2012 19
2013 20
2014 25
2015 22
2016 17
2017 27
2018 21
2019 30
2020 28
2021 22
2022 33
2023 22
2024 15
2025 33
2026 11

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

468 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean liu ll[Author] (1,380 results)?
ESMO Adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumours.
Saini KS, Koopman M, Martins-Branco D, Bossi P, Winther SB, Brahmi M, Braña I, Calvo E, Castelo-Branco L, Colombo I, de Azambuja E, De Ruysscher D, Dienstmann R, Dingemans AC, Ekholm M, Gallois C, Golfinopoulos V, Grande E, Halabi S, Le Rhun E, Le Saux O, Leighl NB, Lonardi S, Lorenzen S, Lorusso D, Minniti G, Mountzios G, Oldenburg J, Oosting SF, Osterlund P, Perez-Gracia JL, Pellat A, Piperno-Neumann S, Plummer R, Porta C, Punie K, Ray-Coquard I, Remon J, Ruhlmann CH, Rutkowski P, Siu LL, Stacchiotti S, Suarez C, Suijkerbuijk K, Taieb J, Trapani D, Valachis A, van Laarhoven HWM, Vogel A, Zer A, Pentheroudakis G, Delaloge S, Twelves C. Saini KS, et al. Among authors: siu ll. Ann Oncol. 2026 Feb 17:S0923-7534(26)00064-5. doi: 10.1016/j.annonc.2026.02.008. Online ahead of print. Ann Oncol. 2026. PMID: 41713786
Clinical validation of a tissue-agnostic genome-wide methylome enrichment assay to monitor response to pembrolizumab.
Stutheit-Zhao EY, Zhong Y, Melton CA, Lightbody ED, Hinterberg MA, Wang Y, Hall O, Sosa EV, Provance JB, Zhang J, Licon A, Liu ZA, Abdul Razak AR, Spreafico A, Bedard PL, Hansen AR, Lheureux S, Ohashi PS, Williams A, Bratman SV, Allen BA, Zhang J, De Carvalho DD, Hartman AR, Siu LL, Sanz-Garcia E. Stutheit-Zhao EY, et al. Among authors: siu ll. NPJ Precis Oncol. 2026 Feb 13. doi: 10.1038/s41698-026-01327-y. Online ahead of print. NPJ Precis Oncol. 2026. PMID: 41688797 Free article.
Analysis of Plasma Epstein-Barr Virus DNA and Clinical Outcomes to Pembrolizumab or Chemotherapy in Recurrent/Metastatic Nasopharyngeal Cancer in KEYNOTE-122.
Chan ATC, Lee VHF, Hong RL, Ahn MJ, Chong WQ, Spreafico A, Kim SB, Ho GF, Caguioa PB, Ngamphaiboon N, Swaby RF, Wei B, Webber AL, Kang J, Gumuscu B, Yuan J, Siu LL. Chan ATC, et al. Among authors: siu ll. Cancer Med. 2026 Feb;15(2):e71496. doi: 10.1002/cam4.71496. Cancer Med. 2026. PMID: 41631899 Free PMC article. Clinical Trial.
Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial.
Rose AAN, Maxwell J, Rousselle E, Mukonoweshuro CL, Elkholi IE, Riaud M, Biondini M, Cianfarano E, Soria-Bretones I, Tobin C, McGuire M, Law RWY, Elia AJ, Wang BX, King I, Zhang T, Pugh TJ, Kamil ZS, Butler M, Shepherd FA, Leighl NB, Razak AA, Hansen A, Saibil SD, Bedard PL, Siegel PM, Siu LL, Cescon DW, Spreafico A. Rose AAN, et al. Among authors: siu ll. Nat Commun. 2026 Jan 3;17(1):1323. doi: 10.1038/s41467-025-68076-7. Nat Commun. 2026. PMID: 41484121 Free PMC article. Clinical Trial.
Investigating Early Kinetics in Plasma ctDNA and Peripheral T-cell Receptor Repertoire to Predict Treatment Outcomes to PD-1 Inhibitors in Head and Neck Squamous Cell Carcinoma.
Sanz-Garcia E, Soleimani S, Bruce JP, Pedersen S, Tang M, Avery L, Eagles J, Spreafico A, Hansen AR, Eng L, Laliotis G, Krainock M, Liu M, Basra P, Yu C, Felicen S, Ohashi PS, Bratman SV, Pugh TJ, Siu LL. Sanz-Garcia E, et al. Among authors: siu ll. Clin Cancer Res. 2026 Feb 17;32(4):735-747. doi: 10.1158/1078-0432.CCR-25-3541. Clin Cancer Res. 2026. PMID: 41417470
Cancer in 2025.
Siu LL; AACR Cancer Progress Report 2025 Steering Committee. Siu LL, et al. Cancer Discov. 2025 Dec 2;15(12):2408-2413. doi: 10.1158/2159-8290.CD-25-1782. Cancer Discov. 2025. PMID: 41327970
Safety and efficacy of intratumourally administered INT230-6 in adult patients with advanced solid tumours: results from an open-label phase 1/2 dose escalation study.
Thomas JS, Siu LL, Ingham M, Azad NS, Meyer CF, Olszanski AJ, Whalen GF, Camacho LH, Hu JS, Hanna DL, Cheng PM, Abdul Razak AR, Abbate F, Mahmood S, Walters IB, Bender LH, El-Khoueiry AB. Thomas JS, et al. Among authors: siu ll. EBioMedicine. 2025 Nov;121:105980. doi: 10.1016/j.ebiom.2025.105980. Epub 2025 Oct 29. EBioMedicine. 2025. PMID: 41168074 Free PMC article. Clinical Trial.
468 results